How to buy Altimmune shares

Own Altimmune shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Altimmune, Inc is a biotechnology business with stocks listed in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$12.95 – an increase of 2.37% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Altimmune

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Altimmune. Find the share by name or ticker symbol: ALT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Altimmune reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$12.95, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Altimmune, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Altimmune. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Altimmune share price

Use our graph to track the performance of ALT stocks over time.

Altimmune shares at a glance

Information last updated 2021-06-10.
52-week rangeUS$6.88 - US$35.1
50-day moving average US$13.3403
200-day moving average US$14.3003
Target priceUS$40.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-4.161

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Altimmune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Altimmune price performance over time

Historical closes compared with the last close of $12.95

1 week (2021-06-03) 0.23%
1 month (2021-05-13) 1.65%
3 months (2021-03-12) -22.73%
6 months (2020-12-11) 8.19%
1 year (2020-06-12) 71.75%
2 years (2019-06-13) 422.18%
3 years (2018-06-13) -14.15%
5 years (2016-06-13) -98.00%

Altimmune financials

Revenue TTM US$6.8 million
Gross profit TTM US$-25,324,291
Return on assets TTM -18.43%
Return on equity TTM -41.63%
Profit margin 0%
Book value 6.464
Market capitalisation US$546.8 million

TTM: trailing 12 months

Shorting Altimmune shares

There are currently 4.2 million Altimmune shares held short by investors – that's known as Altimmune's "short interest". This figure is 19.7% down from 5.3 million last month.

There are a few different ways that this level of interest in shorting Altimmune shares can be evaluated.

Altimmune's "short interest ratio" (SIR)

Altimmune's "short interest ratio" (SIR) is the quantity of Altimmune shares currently shorted divided by the average quantity of Altimmune shares traded daily (recently around 949779.1011236). Altimmune's SIR currently stands at 4.45. In other words for every 100,000 Altimmune shares traded daily on the market, roughly 4450 shares are currently held short.

However Altimmune's short interest can also be evaluated against the total number of Altimmune shares, or, against the total number of tradable Altimmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Altimmune's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Altimmune shares in existence, roughly 110 shares are currently held short) or 0.1264% of the tradable shares (for every 100,000 tradable Altimmune shares, roughly 126 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Altimmune.

Find out more about how you can short Altimmune stock.

Altimmune share dividends

We're not expecting Altimmune to pay a dividend over the next 12 months.

Have Altimmune's shares ever split?

Altimmune's shares were split on a 1:30 basis on 13 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.

Altimmune share price volatility

Over the last 12 months, Altimmune's shares have ranged in value from as little as US$6.88 up to US$35.1. A popular way to gauge a stock's volatility is its "beta".

ALT.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.3154. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Altimmune overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform